NCT07478302 A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma
| NCT ID | NCT07478302 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Condition | Advanced Unresectable Hepatocellular Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 36 participants |
| Start Date | 2026-04-14 |
| Primary Completion | 2027-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 36 participants in total. It began in 2026-04-14 with a primary completion date of 2027-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma. Blood samples were obtained during the course of treatment to measure the relative parameter. All Investigational Medicinal Products (IMP) were discontinued after the total cycle.
Eligibility Criteria
Inclusion Criteria: 1. ≥ 18 years old; 2. Advanced hepatocellular carcinoma (HCC) confirmed by histopathology or cytology or clinical diagnosis; 3. The Barcelona clinical liver cancer stage was B or C; 4. Has not previously received systemic antitumor therapy for HCC; 5. At least one measurable lesion according to RECIST v1.1 criteria; 6. Child-Pugh score of A or B7 ; 7. ECOG score 0 -1; 8. The expected survival time was ≥12 weeks; 9. The major organs functioned well; 10. Has signed the informed consent form. Exclusion Criteria: 1. Hepatobiliary cell carcinoma, mixed hepatocellular carcinoma-cholangiocarcinoma, sarcomatoid hepatocellular carcinoma, and fibrolamellar hepatocellular carcinoma confirmed by histology or cytology; 2. Patients with active malignant tumors other than HCC within 5 years or at the same time; Localized tumors that had been cured, such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, prostate cancer in situ, cervical cancer in situ, and breast cancer in situ, could be enrolled; 3. Previous allogeneic organ transplantation (e.g., liver transplantation); 4. The current liver tumor burden is greater than 50% of the total liver volume; 5. CTCAE grade 3 bleeding had occurred within 6 months or CTCAE grade 2 nongastrointestinal bleeding had occurred within 3 months before the first dose; 6. Abdominal fistula, gastrointestinal perforation, or abdominal abscess within 6 months before the first dose; 7. Major vascular disease had occurred within 6 months before the first dose; 8. Current concomitant interstitial pneumonia or interstitial lung disease, or a previous history of interstitial pneumonia or interstitial lung disease requiring hormone therapy; 9. Innate or acquired immune deficiency (such as HIV infection); 10. Severe infection occurred within 28 days before the first dose.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07478302 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advanced Unresectable Hepatocellular Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07478302 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07478302 currently recruiting?
Yes, NCT07478302 is actively recruiting participants. Contact the research team at yang.wu.yw96@hengrui.com for enrollment information.
Where is the NCT07478302 trial being conducted?
This trial is being conducted at Fuzhou, China, Nanning, China.
Who is sponsoring the NCT07478302 clinical trial?
NCT07478302 is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. The trial plans to enroll 36 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.